Heterologous Immunity Between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens
Overview
Biophysics
Cell Biology
Molecular Biology
Affiliations
Host immune responses play an important role in the outcome of infection with hepatitis C virus (HCV). They can lead to viral clearance and a positive outcome, or progression and severity of chronic disease. Extensive research in the past >25 years into understanding the immune responses against HCV have still resulted in many unanswered questions implicating a role for unknown factors and events. In our earlier studies, we made a surprising discovery that peptides derived from structural and non-structural proteins of HCV have substantial amino acid sequence homologies with various proteins of adenoviruses and that immunizing mice with a non-replicating, non-recombinant adenovirus vector leads to induction of a robust cross-reactive cellular and humoral response against various HCV antigens. In this work, we further demonstrate antibody cross-reactivity between Ad and HCV in vivo. We also extend this observation to show that recombinant adenoviruses containing antigens from unrelated pathogens also possess the ability to induce cross-reactive immune responses against HCV antigens along with the induction of transgene antigen-specific immunity. This cross-reactive immunity can (a) accommodate the making of dual-pathogen vaccines, (b) play an important role in the natural course of HCV infection and (c) provide a plausible answer to many unexplained questions regarding immunity to HCV.
Zhu J, He C, Liu Y, Chen M, Zhang J, Chen D Front Microbiol. 2024; 15:1472824.
PMID: 39588106 PMC: 11586386. DOI: 10.3389/fmicb.2024.1472824.
Costa G, Sautto G Vaccines (Basel). 2024; 12(8).
PMID: 39204016 PMC: 11359689. DOI: 10.3390/vaccines12080890.
Patel R, Agrawal B Front Immunol. 2023; 14:1178523.
PMID: 37334376 PMC: 10272440. DOI: 10.3389/fimmu.2023.1178523.
The use of adenoviral vectors in gene therapy and vaccine approaches.
Araujo N, Rubio I, Toneto N, Morale M, Tamura R Genet Mol Biol. 2022; 45(3 Suppl 1):e20220079.
PMID: 36206378 PMC: 9543183. DOI: 10.1590/1678-4685-GMB-2022-0079.
Xiao Y, Xu H, Guo W, Zhao Y, Luo Y, Wang M Mol Biomed. 2021; 1(1):16.
PMID: 34765999 PMC: 7711057. DOI: 10.1186/s43556-020-00017-w.